Autoantibodies to Erythropoietin Receptor and Clinical Outcomes in Patients With Type 2 Diabetes and CKD: A Post Hoc Analysis of CREDENCE Trial

Autoantibodies to Erythropoietin Receptor and Clinical Outcomes in Patients With Type 2 Diabetes and CKD: A Post Hoc Analysis of CREDENCE Trial

Introduction: Autoantibodies to erythropoietin receptor (anti-EPOR antibodies) have been identified in patients with various kidney diseases. However, data in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) is limited. We assessed the prevalence of anti-EPOR antibodies and their...

Full description

Saved in:
Bibliographic Details
Main Authors: Akihiko Koshino, Brendon L. Neuen, Megumi Oshima, Tadashi Toyama, Akinori Hara, Clare Arnott, Bruce Neal, Meg Jardine, Sunil V. Badve, Kenneth W. Mahaffey, Carol Pollock, Michael K. Hansen, Takashi Wada, Hiddo J.L. Heerspink
Format: Article
Language:English
Published: Elsevier 2024-02-01
Series:Kidney International Reports
Subjects:
anemia
biomarker
cardiovascular
kidney
mortality
SGLT2 inhibitor
Online Access:http://www.sciencedirect.com/science/article/pii/S2468024923016133
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2468024923016133

Similar Items